1-20 of 21
Robin Humphreys
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2145: High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models

Aparna Gupta, Kedar S. Vaidya, Janneke J.T.M. Melis, Robert Hauptschein, Graham Brock, Robin Humphreys
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2145.
https://doi.org/10.1158/1538-7445.AM2023-2145
Published: 04 April 2023
View article titled, Abstract 2145: High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models
Journal Articles

Abstract 4037: In vitro cytotoxicity of CPX-351 plus venetoclax compared with hypomethylating agents or cytarabine plus venetoclax

Aparna Gupta, Robin Humphreys, Derek Hanson, Qi Wang
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4037.
https://doi.org/10.1158/1538-7445.AM2020-4037
Published: 15 August 2020
View article titled, Abstract 4037: <em>In vitro</em> cytotoxicity of CPX-351 plus venetoclax compared with hypomethylating agents or cytarabine plus venetoclax
Journal Articles

Abstract LB-222: Optimization and preclinical characterization of highly potent and stable anti-CD70 ADCs for the potential treatment of CD70 positive cancers

Lillian Skidmore, Kari Cox, Jessica Kirtley, Tiep Le, Juhi Firdos, Anthony Manibusan, Shiao-Yan Fang, Andy Beck, Shiva Bhowmik, Nick Knudsen, Jianing Wang, Ying Sun, Armando Ayala, Alyssa Powell, Alan Wahl, Feng Tian, Robin Humphreys
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): LB-222.
https://doi.org/10.1158/1538-7445.AM2016-LB-222
Published: 15 July 2016
View article titled, Abstract LB-222: Optimization and preclinical characterization of highly potent and stable anti-CD70 ADCs for the potential treatment of CD70 positive cancers
Journal Articles

Abstract 1876: Preclinical efficacy of fibroblast growth factor ligand trap HGS1036 in lung carcinoma models with genomic amplification of FGFR1

Thomas Harding, Servando Palencia, Tiffany Wallace, Anita Levin, Namrata Patil, Ruby Cheung, Mallory Aguirre, Li Long, Robin Humphreys, Mike Kavanaugh, Kevin Baker
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 1876.
https://doi.org/10.1158/1538-7445.AM2012-1876
Published: 15 April 2012
View article titled, Abstract 1876: Preclinical efficacy of fibroblast growth factor ligand trap HGS1036 in lung carcinoma models with genomic amplification of <em>FGFR1</em>
Journal Articles

Abstract 3861: Fusion toxin BLyS-gelonin inhibits growth of B-NHL cell lines in vitro and in vivo

Troy A. Luster, Ipsita Mukherjee, Jeffrey A. Carrell, Yun Hee Cho, Jeffrey Gill, Andy Garcia, Christopher Ward, Stephen Ullrich, Thi-Sau Migone, Robin Humphreys
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3861.
https://doi.org/10.1158/1538-7445.AM2012-3861
Published: 15 April 2012
View article titled, Abstract 3861: Fusion toxin BLyS-gelonin inhibits growth of B-NHL cell lines <em>in vitro</em> and <em>in vivo</em>
Journal Articles

Abstract 4101: Off-target lapatinib activity up-regulates TRAIL death receptors in colon cancer cells

Nathan G. Dolloff, Patrick Mayes, Lori Hart, David Dicker, Robin Humphreys, Wafik El-Deiry
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4101.
https://doi.org/10.1158/1538-7445.AM2011-4101
Published: 15 April 2011
View article titled, Abstract 4101: Off-target lapatinib activity up-regulates TRAIL death receptors in colon cancer cells
Journal Articles

Abstract #5131: Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody resistant NSCLC cell lines when treated in combination with bortezomib

Troy Luster, Jeffrey Carrell, Robin Humphreys
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 5131.
Published: 01 May 2009
View article titled, Abstract #5131: Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody resistant NSCLC cell lines when treated in combination with bortezomib
Journal Articles

Abstract #5118: Requirement of both isoforms of TRAIL-R2 (DR5) in death receptor signaling.

Kristi Peters, Ke Yang, Jennifer DeVecchio, Robin Humphreys, Janet Houghton
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 5118.
Published: 01 May 2009
View article titled, Abstract #5118: Requirement of both isoforms of TRAIL-R2 (DR5) in death receptor signaling.
Journal Articles

Abstract #3240: Agonistic antibody to TRAIL-R1 (Mapatumumab) and low dose Bortezomib induce apoptosis in multiple myeloma while preserving dendritic cell function

Paul Neeson, Karen Chen, Tsin Tai, Amanda Shin, Kellie Tainton, Kate Fielding, Joanne Davis, H. Prince, Robin Humphreys, David Ritchie
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3240.
Published: 01 May 2009
View article titled, Abstract #3240: Agonistic antibody to TRAIL-R1 (Mapatumumab) and low dose Bortezomib induce apoptosis in multiple myeloma while preserving dendritic cell function
Journal Articles

A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR

Bin Ren, Keli Song, Sareh Parangi, Taiguang Jin, Min Ye, Robin Humphreys, Mark Duquette, Xuefeng Zhang, Nordine Benhaga, Jack Lawler, Roya Khosravi-Far
Journal: Cancer Research
Cancer Res (2009) 69 (9): 3856–3865.
https://doi.org/10.1158/0008-5472.CAN-08-2940
Published: 30 April 2009
View article titled, A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR
Open the PDF for A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR in another window
Includes: Supplementary data
Journal Articles

Sorafenib sensitizes hepatocellular carcinoma cells to TRAIL or TRAIL receptor agonist antibodies

Junaid Abdulghani, Patrick Mayes, David Dicker, Charles Smith, Robin Humphreys, Wafik El Deiry
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 833.
Published: 01 May 2008
View article titled, Sorafenib sensitizes hepatocellular carcinoma cells to TRAIL or TRAIL receptor agonist antibodies
Journal Articles

The role of TRAIL receptors in therapeutic response of human colorectal cancer (cc)

Ke Yang, Yang Guo, Steffan Nawrocki, Jennifer DeVecchio, Tanvi Jani, Robin Humphreys, Janet Houghton
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 831.
Published: 01 May 2008
View article titled, The role of TRAIL receptors in therapeutic response of human colorectal cancer (cc)
Journal Articles

Novel target of lapatinib enhances anti-tumor activity via TRAIL sensitization

Nathan Dolloff, Patrick Mayes, David Dicker, Robin Humphreys, Wafik El-Deiry
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 835.
Published: 01 May 2008
View article titled, Novel target of lapatinib enhances anti-tumor activity via TRAIL sensitization
Journal Articles

The TRAIL Receptor 1 antibody, Mapatumumab, synergizes with cisplatin or doxorubicin to enhance anti-tumor activity in hepatocellular carcinoma

Robin Humphreys, Kathy McCormick, Lenny Taslim, Carol Poortman, Jeff Carrell
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 1561.
Published: 01 May 2008
View article titled, The TRAIL Receptor 1 antibody, Mapatumumab, synergizes with cisplatin or doxorubicin to enhance anti-tumor activity in hepatocellular carcinoma
Journal Articles

Histone Deacetylase Inhibitors Enhance Lexatumumab-Induced Apoptosis via a p21Cip1-Dependent Decrease in Survivin Levels

Steffan T. Nawrocki, Jennifer S. Carew, Leslie Douglas, John L. Cleveland, Robin Humphreys, Janet A. Houghton
Journal: Cancer Research
Cancer Res (2007) 67 (14): 6987–6994.
https://doi.org/10.1158/0008-5472.CAN-07-0812
Published: 17 July 2007
View article titled, Histone Deacetylase Inhibitors Enhance Lexatumumab-Induced Apoptosis via a p21<sup>Cip1</sup>-Dependent Decrease in Survivin Levels
Open the PDF for Histone Deacetylase Inhibitors Enhance Lexatumumab-Induced Apoptosis via a p21<sup>Cip1</sup>-Dependent Decrease in Survivin Levels in another window
Includes: Supplementary data
Journal Articles

Synergistic anti-tumor effect with combination of a novel small molecule Smac mimetic compound (SM-164) and agonist TRAIL-R monoclonal Abs (Mapatumumab & Lexatumumab).

Nathalie Bruey-Sedano, Carol Poortman, Xiongwen Zhang, Yan Zhang, Guangfeng Wang, Ping Min, Xinyan Ni, Lidong Xing, Yanqiong Lin, Xiaolan Ling, Robin Humphreys, Dajun Yang
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 4871.
Published: 01 May 2007
View article titled, Synergistic anti-tumor effect with combination of a novel small molecule Smac mimetic compound (SM-164) and agonist TRAIL-R monoclonal Abs (Mapatumumab &amp; Lexatumumab).
Journal Articles

Activitating TRAIL death receptors with human agonist monoclonal antibodies

Robin Humphreys
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): SY13-01.
Published: 01 May 2007
View article titled, Activitating TRAIL death receptors with human agonist monoclonal antibodies
Journal Articles

Bortezomib sensitizes TRAIL-R mAb resistant NSCLC tumors to apoptosis in combination with TRAIL-R agonistic mAbs: Mapatumumab (HGS-     ETR     1) and Lexatumumab (HGS-     ETR     2)

David Sun, Kathy McCormick, Lenny Taslim, Jeffrey Carrell, Lindsey Shepard, Robin Humphreys
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 5177.
Published: 01 May 2007
View article titled, Bortezomib sensitizes TRAIL-R mAb resistant NSCLC tumors to apoptosis in combination with TRAIL-R agonistic mAbs: Mapatumumab (HGS-     ETR     1) and Lexatumumab (HGS-     ETR     2)
Journal Articles

Ligation of TRAIL receptors synergistically enhances therapeutic response to 5-fluorouracil (FUra), leucovorin (LV) and interferon-γ (IFN-γ) in human colon carcinoma cell lines (cc) both in vitro and in xenograft models

Steffan Nawrocki, Leslie Douglas, David M. Tillman, Robin Humphreys, Janet A. Houghton
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 127.
Published: 15 April 2006
View article titled, Ligation of TRAIL receptors synergistically enhances therapeutic response to 5-fluorouracil (FUra), leucovorin (LV) and interferon-γ (IFN-γ) in human colon carcinoma cell lines (cc) both in vitro and in xenograft models
Journal Articles

Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in ovarian tumor lines and their activity is enhanced by taxol and carboplatin.

Ronald L. Johnson, Danielle Gillotte, Carol Poortman, Lily Zhang, Xiuli Huang, Michele Fiscella, Robin Humphreys, Vivian Albert
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 826.
Published: 01 April 2004
View article titled, Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in ovarian tumor lines and their activity is enhanced by taxol and carboplatin.